There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …

Radioiodine treatments of patients with well-differentiated thyroid carcinoma have generally
been safe and beneficial. Safety can be ensured while efficacy is increased through …

This short review focuses on two questions commonly asked about 131I therapy of thyroid
cancer. The first relates to radiation dosimetry. What percentage of 131I uptake is needed for …

SUMMARY Altogether, 147 scintiscans, completed 48–72 h after 74 MBq 131 I, were
compared with scintiscans obtained on average 7.8 days after therapeutic doses of 131 I …

131I treatment in thyroid cancer patients may induce side effects, including extrathyroidal
cancer and leukemia. There are still some uncertainties concerning parameters that may …

Background: Dosimetry has been used to help identify when empiric dosages of 131-I
treatment for suspected metastatic well-differentiated thyroid carcinoma (WDTC) may be …

In some patients with well-differentiated thyroid carcinoma, dosimetry is necessary to avoid
toxicity from therapy and to guide prescription of the administered activity of radioiodine …

For almost five decades, 131I treatment of thyroid cancer has been based empirically on
administered activity rather than on actual radiation doses delivered. In 1983, we defined …

Iodine-131 for Differentiated Thyroid Carcinoma Page 1 Biological Dosimetry in Patients Treated
with Iodine-131 for Differentiated Thyroid Carcinoma R. M’Kacher, JD Legal, M. Schlumbcrger …

Based on pre-therapy whole-body 131 I scintiscans showing only residual thyroid, 64
patients with differentiated thyroid cancer were treated with 1100 MBq (< 30 mCi) 131 I as …